Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Personalized Medicine Drives Uptake of Next-generation Sequencing in Europe

Published: Saturday, May 31, 2014
Last Updated: Saturday, May 31, 2014
Bookmark and Share
Future of DNA sequencing will shift from a laboratory-based setup to point of care testing in the next 5 years.

The Western European next-generation sequencing (NGS) market is poised for steady growth, owing to the emergence of new applications such as non-invasive prenatal testing and comprehensive oncology panels.

NGS manufacturers are further tapping into this space by forming partnerships with molecular diagnostic companies to quicken NGS adoption in clinics, particularly for oncology-based testing.

New analysis from Frost & Sullivan, Western European Next-generation Sequencing Markets, finds that the market earned revenues of $381.9 million in 2013 and estimates this to reach $697.3 million in 2018.

Major growth areas will include pre-implantation genetic diagnosis, oncology testing, infectious disease, human leukocyte antigen typing, and companion diagnostics. The total market, as defined by this study, includes next-generation sequencers and reagents for both research and diagnostic use.

“Companies within the space of personalized healthcare are designing instruments to target specific needs across the clinical diagnostic spectrum, therefore adding NGS capabilities to their portfolio,” said Frost & Sullivan Healthcare Senior Industry Analyst Divyaa Ravishankar. “As long as the genomic era interfaces with personalized medicine, NGS uptake will continue.”

A key restraint curbing market potential is the lack of reimbursement norms, which leads to geographical disparity in terms of NGS test availability. The consequent need for the cross-border shipping of samples, prominent in Belgium, France, Italy, Spain, the UK, and Germany, makes gauging the reimbursement scenario extremely tough for market participants.

Hence, NGS vendors must establish early, robust partnerships with regulatory bodies and devise effective business models to gain rapid regulatory clearance. Manufactures must also look to adhere to the CE marking rather than laboratory developed test (LDT) policies to enable the easy generation of reimbursement codes.

“Given the recent technology advancements in Europe, the future of DNA sequencing will move away from a laboratory-based setup to point of care testing,” predicted Ravishankar. “Frost & Sullivan expects NGS to become an area of interest to all market leaders within the point of care testing domain, as they strive to bring sequencing from ‘bench to bedside’.”

As the applications of NGS and molecular diagnostics expand to include crop improvement as well as food and safety testing, ready-to-use sequencing-based tests that generate data from raw samples will emerge as important tools in the Western European market.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Changing Phase of Biomarkers
Discover the current scenario and changing business models of the biomarkers field.
Monday, April 13, 2015
Gene Expression Profiling Drives Personalized Medicine Worldwide
Large amounts of information generated by gene expression profiling will increase implementation of data management tools.
Tuesday, June 10, 2014
Increasing Prevalence of Heart Disease Drives Growth of Cardiac Biomarkers Diagnostics Market
Participants need to focus on product customization, ease-of-use and reliability.
Monday, April 22, 2013
Next Generation Sequencing on the European Growth Path
Next Generation Sequencers have found their way into labs and the global biomedical research community. 2010 has seen a serious uptake of Next Generation Sequencing technology, and today it is perceived as an indispensable tool for researchers.
Wednesday, January 26, 2011
Converging towards Integrated Healthcare: A Frost & Sullivan Think Tank on Megatrends Affecting the Healthcare Industry
A clear separation between Medical Devices, Healthcare Technologies and Life Sciences is increasingly difficult. Yet the convergence of all areas opens the door to a new era, enabling personalisation, targeted medicines, new drug delivery mechanisms, and virtual patient monitoring tools, while allowing a preventative approach to healthcare at the same time.
Friday, October 08, 2010
Frost & Sullivan: Finding Healthcare's 'Holy Grail'
Faced with escalating treatment costs and pressure to be affordable while searching for efficiency and better quality, hospitals are turning towards Health IT (HIT) for assistance where patient care is no longer the sole responsibility of doctors and nurses alone.
Friday, July 09, 2010
Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
Genetic Signature Linked to Cancer Prognosis Identified
The results of the analysis of 8,161 tissue samples could in the future help clinicians decide how best to treat a patient as well as aid the development of new targeted treatments.
NIH Commits $6.7 M to Advance DNA, RNA Sequencing Technology
"Can you believe they make DNA sequencers the size of staplers?" asked Meni Wanunu, Ph.D. "Ideas that were crazy twenty years ago are now happening!"
Curcumin Shows Promise as Cancer Treatment
When delivered at the correct circadian phase, curcumin demonstrates sustained toxicity in cancer cells and should be considered for use in patient care.
"Junk" DNA Critical for Heart Function
Loss of noncoding elements of genome, known as enhancers, results in abnormalities of heart functions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos